Zobrazeno 1 - 10
of 1 085
pro vyhledávání: '"CEFTOLOZANE/TAZOBACTAM"'
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 38, Iss , Pp 216-222 (2024)
ABSTRACT: Objectives: Ceftolozane-tazobactam (C/T) is a combination of a cephalosporin and a β-lactamase inhibitor with activity against Gram-negative bacilli (GNB). The study aims were to evaluate the activity of C/T in vitro vs. comparators agains
Externí odkaz:
https://doaj.org/article/394ee0cab1a54a768b0fde7ca69ed98b
Publikováno v:
Pathogens and Immunity, Vol 9, Iss 2 (2024)
Background: The potential for promotion of intestinal colonization with healthcare-associated pathogens by new antibiotics used to treat infections due to multidrug-resistant Gram-negative bacilli is unclear. Methods: Mice treated for 3 days with d
Externí odkaz:
https://doaj.org/article/6dce3915fd9a4408999db5ec82cbcfc3
Publikováno v:
BMC Health Services Research, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Resistant bacterial infections, particularly those caused by gram-negative pathogens, are associated with high mortality and economic burdens. Ceftolozane/tazobactam demonstrated efficacy comparable to meropenem in patients with v
Externí odkaz:
https://doaj.org/article/a8dff5c954aa47928cb219cb8dfc6a54
Autor:
Viviane de C. Oliveira, Alba Soler-Comas, Amanda C.S.D. Rocha, Cláudia H. Silva-Lovato, Evandro Watanabe, Antoni Torres, Laia Fernández-Barat
Publikováno v:
Emerging Microbes and Infections, Vol 13, Iss 1 (2024)
Although an increased effectiveness has been suggested when phages and antibiotics are combined, this approach has not been tested against a mature biofilm on an endotracheal tube (ETT) surface. This study evaluated the effect of short- and long-term
Externí odkaz:
https://doaj.org/article/3db6eefb5ade4bf59d923a14451b01d9
Autor:
Anne Santerre Henriksen, Fabio Arena, Marie Attwood, Rafael Canton, Sören Gatermann, Thierry Naas, Ian Morrissey, Christopher Longshaw
Publikováno v:
Microbiology Spectrum, Vol 12, Iss 8 (2024)
ABSTRACT Carbapenem-resistant Enterobacterales represent a major health threat and have few approved therapeutic options. Enterobacterales isolates were collected from hospitalized inpatients from 49 sites in six European countries (1 January–31 De
Externí odkaz:
https://doaj.org/article/1f3d1d994d1a4cbbb99acb1bfe3c5808
Autor:
Chien-Ming Chao, Wen-Liang Yu
Publikováno v:
Heliyon, Vol 10, Iss 13, Pp e33114- (2024)
Ceftolozane, a novel cephalosporin, combined with tazobactam, a known β-lactamase inhibitor, shows robust antipseudomonal activity, although it doesn't cover carbapenemases. Our review of data from 2012 to 2021 in Taiwan highlights TOL/TAZ's in-vitr
Externí odkaz:
https://doaj.org/article/047ae70b731e4b9681647a6ba57ad645
Autor:
Mihai Octavian Dan, Daniela Tǎlǎpan
Publikováno v:
Frontiers in Microbiology, Vol 15 (2024)
Gram-negative bacteria have been one of the most studied classes in the field of microbiology, especially in the context of globally alarming antimicrobial resistance levels to these pathogens over the course of the past decades. With high numbers of
Externí odkaz:
https://doaj.org/article/3ed6ca5f04ad4a6f826945a9201cc14c
Autor:
James A. Karlowsky, Mark G. Wise, Tai-Chin Hsieh, Hung-Chi Lu, Wei-Ting Chen, Ming-Huei Cheng, Fakhar Siddiqui, Katherine Young, Mary R. Motyl, Daniel F. Sahm
Publikováno v:
Journal of Global Antimicrobial Resistance, Vol 34, Iss , Pp 106-112 (2023)
ABSTRACT: Objectives: To determine the in vitro activities of ceftolozane/tazobactam (C/T) and comparators against Pseudomonas aeruginosa isolates cultured from hospitalised patient samples in Taiwan from 2012 to 2021 with an additional focus on the
Externí odkaz:
https://doaj.org/article/3e5e47fbc6ff4a82ae065a886c5d8f5b
Autor:
Jade L. L. Teng, Elaine Chan, Tsz Tuen Li, Tsz Ying Kwan, Ka Fai Chan, Wing Ho Li, Viki W. K. Tang, Man Lung Yeung, Susanna K. P. Lau, Patrick C. Y. Woo
Publikováno v:
Antibiotics, Vol 13, Iss 9, p 802 (2024)
Due to the increasing resistance of aerobic and facultative anaerobic Gram-negative rods, ceftazidime-avibactam and ceftolozane-tazobactam have been launched in the market in the last few years. In this study, we analyzed the susceptibility pattern o
Externí odkaz:
https://doaj.org/article/322469988fee4876ad4c29d4727730a3
Autor:
Wasim S. El Nekidy, Mooza Al Ali, Emna Abidi, Rania El Lababidi, Diaa Alrahmany, Islam M. Ghazi, Mohamad Mooty, Fadi Hijazi, Muriel Ghosn, Jihad Mallat
Publikováno v:
Antibiotics, Vol 13, Iss 8, p 699 (2024)
The optimal doses of ceftazidime–avibactam (CZA) and ceftolozane–tazobactam (C/T) for treating multidrug-resistant (MDR) Pseudomonas aeruginosa (PSA) in patients utilizing renal replacement therapy (RRT) are not well established. Hence, the objec
Externí odkaz:
https://doaj.org/article/80d5d2a1c0414dcb8eb4d9060cb58a55